Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Non-Current Debt (2016 - 2025)

Haemonetics has reported Non-Current Debt over the past 16 years, most recently at $920.0 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 24.58% year-over-year to $920.0 million; the TTM value through Dec 2025 reached $920.0 million, down 24.58%, while the annual FY2025 figure was $921.2 million, 15.51% up from the prior year.
  • Non-Current Debt for Q4 2025 was $920.0 million at Haemonetics, roughly flat from $920.4 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $1.2 billion in Q4 2024 and troughed at $559.4 million in Q2 2022.
  • A 5-year average of $843.8 million and a median of $765.2 million in 2021 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: surged 158.46% in 2021 and later dropped 24.58% in 2025.
  • Year by year, Non-Current Debt stood at $698.0 million in 2021, then increased by 8.42% to $756.8 million in 2022, then grew by 13.22% to $856.8 million in 2023, then soared by 42.35% to $1.2 billion in 2024, then dropped by 24.58% to $920.0 million in 2025.
  • Business Quant data shows Non-Current Debt for HAE at $920.0 million in Q4 2025, $920.4 million in Q3 2025, and $920.8 million in Q2 2025.